Goldman Sachs Group Inc. disclosed the purchase of 500,000 shares of Attovia Therapeutics, Inc. (ATTO) on the open market on August 6, 2026, according to a Form 4 filed with the SEC. The shares were bought at $17.00 apiece for a total outlay of $8,500,000. Following the transaction, Goldman Sachs holds 3,020,632 shares indirectly, through a trust or affiliated entity structure rather than in its own name.
The purchase does not stand alone. It is the larger of two open-market buys in Attovia Therapeutics stock recorded within a single 24-hour window, August 5 through August 6, 2026, that together total $10,285,000. Multiple insiders committing capital to the same stock in such a tight timeframe is the kind of pattern that gets flagged internally as a cluster buy, and it is the central fact of this filing rather than the size of any one trade.
Other Buyers in the Same Window
Attovia Therapeutics has already drawn attention from other insiders in recent days. venBio disclosed a $6.5 million purchase of Attovia stock, and Sanofi separately reported a $5.1 million buy, both covered previously on this site. Readers can find more detail on the venBio transaction in our earlier report: ATTO: venBio Buys $6.5M in Attovia Therapeutics Stock. The Goldman Sachs purchase reported here, combined with these other filings, points to a concentrated period of insider buying activity around the same ticker.
Academic research on insider trading disclosures has found that clustered buying, meaning multiple insiders purchasing shares independently within a short window, has historically correlated with periods of subsequent outperformance more often than isolated single-insider purchases. That said, this observation reflects broad historical patterns across many companies and filings, not a prediction or endorsement tied to Attovia Therapeutics specifically. Each Form 4 filing simply documents a completed transaction and the insider’s resulting ownership stake; it does not indicate intent for future trades.
Goldman Sachs Group Inc.’s classification as an ‘Insider’ on this filing reflects its reporting obligation under securities law given its position relative to Attovia Therapeutics, rather than an operational role at the company. The indirect holding structure noted in the filing is common among institutional filers and typically reflects ownership through investment vehicles rather than direct personal accounts.
Further SEC filings related to Attovia Therapeutics may clarify whether this window of buying activity was an isolated event or the start of a broader trend among the company’s insiders and institutional holders.
→ See all ATTO coverage on WhoIsBuyingNow
Source: original SEC Form 4 filing.